Research programme: blood disorder therapeutics - Bicycle Therapeutics/Bioverativ

Drug Profile

Research programme: blood disorder therapeutics - Bicycle Therapeutics/Bioverativ

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bicycle Therapeutics
  • Developer Bicycle Therapeutics; Bioverativ
  • Class Coagulants; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Haemophilia; Sickle cell anaemia

Most Recent Events

  • 08 Mar 2018 Bioverativ has been acquired by Sanofi
  • 06 Sep 2017 Bicycle Therapeutics and Bioverativ enter into an agreement for the development of bicycle peptide therapeutics for Sickle cell anaemia and Haemophilia
  • 06 Sep 2017 Early research in Haemophilia in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top